Zevra Therapeutics, Inc. ZVRA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.1%+1.6pp | 84.5%+3.9pp | 80.7%+8.7pp | 72%-6.9pp | 78.8%+10.3pp | |
| Net margin | 101.6%+23.4pp | 78.2%+36.3pp | 41.9%+37.6pp | 4.3%+231pp | -226.6%+220pp | |
| Returns | ||||||
| Return on equity | 100.7%+15.0pp | 85.7%+50.8pp | 34.8%+31.3pp | 3.5%+208pp | -204.8%+3.1pp | |
| Return on invested capital | -0.1%+49.8pp | -49.9%+3.2pp | -53.2%+11.4pp | -64.6%— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.5×+0.1× | 0.4×+0.1× | 0.3×+0.1× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.9×-0.8× | 5.7×-2.9× | 8.6×+0.8× | 7.9×+4.8× | 3×+0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.4× | 0.4×-0.1× | 0.5×-0.1× | 0.5×-1.0× | 1.5×0.0× | |
| Per Share | ||||||
| Book value per share | $3.42+26.5% | $2.70+13.5% | $2.38+14.4% | $2.08+174% | $0.76— | |
| Valuation | ||||||
| Market capitalization | $773.23M+58.2% | $504.43M-5.5% | $533.84M+6.7% | $500.32M+23.4% | $405.33M-8.9% | |
| Price / earnings | 6.2×— | —— | —— | —— | —— | |
| Price / sales | 6.3×-5.7× | 4.7×-1.6× | 6.3×-1.7× | 8.1×-1.9× | 10×-8.9× | |
| Price / book | 3.8×-8.2× | 3.3×-0.7× | 4×-0.3× | 4.3×-5.6× | 9.9×-1.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Zevra Therapeutics, Inc. (ZVRA) runs a 86.1% gross margin and a -103.9% operating margin, with a 101.6% net margin.
- Where do Zevra Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Zevra Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
